Worth reading
65In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
846000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much
Number of shares delivered during the month: 846,000 shares (846,000 new shares and 0 treasury shares transferred)
EVO FUND (allottee of the 10th Series of Stock Acquisition Rights)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to the exercise restriction: 8.6% (846,000 shares delivered across all series / 9,828,500 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise prices during the subject month: ¥119, ¥120, ¥122, ¥125, ¥128, ¥142 and ¥135. Details of the adjustment clause and the adjustment floor: Not disclosed
Number of Stock Acquisition Rights
Total issued: 82,700; exercised during the subject month: 8,460; unexercised as of the end of the month preceding the subject month: 50,160; unexercised as of the end of the subject month: 41,700
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
13 February 2026 issuance: Tenth Series of Stock Acquisition Rights issued to EVO FUND through a third-party allotment (with Exercise Price Adjustment Clause). Issue amount: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 846,000 shares (846,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (allottee of the 10th Series of Stock Acquisition Rights) |
| Dilution Rate | Exercise ratio subject to the exercise restriction: 8.6% (846,000 shares delivered across all series / 9,828,500 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 13,082,500 shares (as of the end of the month preceding the subject month) → Not disclosed |
| Exercise price | Exercise prices during the subject month: ¥119, ¥120, ¥122, ¥125, ¥128, ¥142 and ¥135. Details of the adjustment clause and the adjustment floor: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 82,700; exercised during the subject month: 8,460; unexercised as of the end of the month preceding the subject month: 50,160; unexercised as of the end of the subject month: 41,700 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 13 February 2026 issuance: Tenth Series of Stock Acquisition Rights issued to EVO FUND through a third-party allotment (with Exercise Price Adjustment Clause). Issue amount: Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company does not state a reason.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.